Oruka Therapeutics Quarterly Balance Sheet
NASDAQ: ORKAHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Oruka Therapeutics financial position
As of Jun 30, 2026, Oruka Therapeutics reported total assets of $1.14 billion, up 218.8% from a year earlier against total liabilities of $24.8 million. Shareholders' equity stood at $1.11 billion, or 97.8% of assets. The company held $268.5 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 38.51, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Oruka Therapeutics balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 | Q1 20232023-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 268.47M | 49.52M | 46.94M | 91.25M | 65.40M | 83.57M | 410.88M | 33.28M | 35.90M | 37.43M | 38.49M | 40.16M |
| Short-Term Investments | 605.09M | 339.31M | 290.11M | 257.90M | 263.01M | 265.52M | — | — | — | — | — | — |
| Total Current Assets | 884.56M | 395.25M | 343.86M | 355.16M | 332.01M | 352.08M | 412.95M | 33.82M | 36.67M | 37.59M | 38.89M | 40.76M |
| Property, Plant & Equipment | 275.00K | 318.00K | 288.00K | 253.00K | 174.00K | 159.00K | 160.00K | 4.00K | 7.00K | 10.00K | 13.00K | 17.00K |
| Long-Term Investments | 252.02M | 107.12M | 142.54M | 151.76M | 23.05M | 23.95M | — | — | — | — | — | — |
| Total Assets | 1.14B | 504.48M | 488.62M | 509.25M | 357.42M | 377.11M | 414.09M | 33.84M | 36.71M | 37.86M | 39.18M | 41.08M |
| Accounts Payable | 7.95M | 3.66M | 4.16M | 2.21M | 4.66M | 3.54M | 2.15M | 571.00K | 529.00K | 362.00K | 322.00K | 241.00K |
| Total Current Liabilities | 22.97M | 16.63M | 15.37M | 20.97M | 12.11M | 11.72M | 18.04M | 1.27M | 1.58M | 637.00K | 992.00K | 1.60M |
| Total Liabilities | 24.84M | 17.76M | 16.69M | 22.46M | 13.78M | 12.39M | 18.88M | 1.27M | 1.58M | 841.00K | 1.22M | 1.84M |
| Shareholders' Equity | 1.11B | 486.72M | 471.93M | 486.79M | 343.64M | 364.73M | 342.37M | -28.98M | -7.06M | 37.02M | 37.97M | 39.24M |
| Retained Earnings | -262.18M | -220.98M | -189.16M | -159.57M | -129.30M | -104.72M | -57.94M | -193.43M | -190.75M | -188.74M | -187.65M | -186.23M |
| Net Cash (Debt) | 873.56M | 388.83M | 337.04M | 349.15M | 328.41M | 349.09M | 410.88M | 33.28M | 35.90M | 37.43M | 38.49M | 40.16M |
| Shares Outstanding | 61.07M | 50.17M | 48.72M | 48.38M | 37.45M | 37.44M | 35.00M | 14.51M | 14.50M | 14.50M | 14.41M | 14.41M |
This table shows 12 quarterly periods of Oruka Therapeutics's balance sheet, from Q2 2026 back to Q1 2023, across 13 line items including cash & equivalents, short-term investments, total current assets. Values in USD; B = billions, M = millions. Fiscal periods follow ORKA's reporting calendar. What is a balance sheet?